sions using conventional endoscopic methods. The CDAI is widely used in assessing disease activity; however, clinical symptoms scored by CDAI are not reliable measures of mucosal inflammation. 3 Computerized tomography enterography (CTE) imaging is useful for assessing disease activity in CD but exposes patients to a large dose of radiation during each evaluation, therefore preventing repeated examinations.
INTRODUCTION
Crohn' s disease (CD) is a chronic transmural IBD that can occur throughout the gastrointestinal tract. It is characterized by repeated episodes of exacerbation and regression. Approximately 70% of patients with CD have small-bowel involvement, and 30% of them have disease limited to the small bowel. 1 Mucosal healing has become the treatment target in the management of CD. 2 However, it is difficult to recognize mucosal lesions in patients with small-bowel le-www.irjournal.org respectively. 9 In other study, MRE detected ulcerative lesions in the small intestine with 82.4% sensitivity and 87.6% specificity. 10 In another study assessing ileocolonic CD, MRE imaging was superior to CTE in detecting intestinal strictures and ileal wall enhancement.
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In a recent study, Deepak et al. 12 revealed that radiological response detected with CTE or MRE was associated with a reduction in the long-term risk of hospitalization, surgery, or corticosteroid use among patients with small-bowel CD. However, few studies have evaluated the prognosis of patients with CD in terms of the first MRE findings both at the time of clinical remission and during the clinically active state. Therefore, the purpose of our study was to evaluate the usefulness of MRE imaging in assessing the prognosis of CD. We hypothesized that active inflammatory findings on MRE would be associated with poor prognosis such as relapse, admission, surgery, need for corticosteroids, need for adding other medications, or need for increasing the dose of current medications even in patients with clinical remission of CD.
METHODS

Patients
In this retrospective study, we reviewed the medical records of patients with CD who underwent MRE imaging at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, between December 2012 and March 2016. The purposes of MRE imaging evaluation were divided into 2 categories: evaluation of current CD activity at the time of clinical remission and that during the clinically active state. MRE was performed in order to follow-up after the treatment. The indications for MRE were when the symptoms persisted despite treatment, complications were suspected, inflammatory markers were elevated even with clinical remission, and determination of the appropriateness of current treatment.
The CDAI according to the criteria of Best et al. 13 was used to assess the disease activity of patients with CD. A CDAI score <150 was considered to indicate clinical remission. Clinical relapse was defined as the occurrence or worsening of symptoms, accompanied by an increase in the CDAI score to >150. 14 Descriptions of patient age at CD diagnosis, disease location, and phenotype were based on the Montreal classification. 15 Previous surgery was defined as a prior CD-related surgery that includes major surgeries such as ileocecectomy and small-bowel resection. The exclusion criteria were patient age <18 years, inaccurate diagnosis of CD, <3 months of follow-up, and any contraindications to MRE imaging such as the presence of a pacemaker in patients. Admission was defined as hospitalization for >1 day through the emergency room or outpatient clinic. Surgery was defined as any CD-related surgeries such as small-bowel resection and ileocecectomy. The need for corticosteroids was defined as the addition of any amount of corticosteroids in patients who were not steroid users during the follow-up period after MRE examination. The need for adding other medications or increasing the dose of current medications was defined as the addition of another type of CD medication or increasing the dose of medications used after MRE examination including corticosteroids, respectively. The study was approved by the Institutional Review Board of Severance Hospital (IRB No. 4-2016-0857) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived.
MRE Technique
We used very low concentration of barium suspension (easy Mark 0.1; Taejoon Pharmaceutical, Seoul, Korea) for luminal distension of small bowel. Patients were given 1,350 mL of this solution orally 60 minutes before MRI. A 3-T imaging unit Fig. 1 . Recruitment algorithm. A total of 243 consecutive patients with magnetic resonance enterography (MRE) were enrolled. After 70 patients were excluded according to our exclusion criteria, a total of 173 patients were selected for statistical analysis. ) and apparent diffusion coefficient mapping; and coronal T 1 -weighted spoiled gradient-echo sequences with fat suppression, including unenhanced imaging and dynamic phases sequences 
Image Analysis
The MRE images were reviewed retrospectively by 2 experienced radiologists (J.S.L. and N.S.) who were blinded to the clinical and laboratory findings of the patients. Active inflammation on MRE was defined as the presence of more than one of the following findings: mural thickening >3 mm, mural hyperenhancement, mural edema (increased signal intensity on T 2 -weighted images), comb sign (sign of engorged vasa recta), penetration (sinus tract, fistula, abscess), or restricted diffusion on diffusion-weighted images. [16] [17] [18] [19] [20] Mucosal healing was defined as the absence of any findings of active inflammation.
End Points
The end points were the rates of clinical relapse, admission, surgery, need for corticosteroids, need for adding other medications, or need for increasing the dose of current medications according to the purpose of the MRE examination.
Statistical Analysis
Statistical analyses were conducted by using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were compared by using the two-sample t-test or the MannWhitney U-test. The chi-square test or Fisher exact test was used to analyze categorical data. The cumulative probabilities of clinical relapse, admission, CD-related surgery, need for corticosteroids, need for adding other medications, or need for increasing the dose of current medications were es- 
RESULTS
A total of 173 consecutive patients with CD who met the inclusion criteria were included in this study (Fig. 1) . The baseline characteristics of the patients on the day of MRE examination are summarized in A total of 61 patients were in the clinical remission state, and their baseline characteristics according to the MRE results are detailed in Table 2 . Forty-four patients (72.1%) had active inflammation on MRE, and their median CRP was higher than that of patients with no active inflammation on MRE (P=0.003). The median albumin level was significantly lower in the group with active inflammation than in the group without (P=0.008).
A total of 112 patients were in the clinically active state, and their baseline characteristics are summarized in Table  3 . The median CRP level and ESR were higher in the group with active inflammation (P<0.001 and P<0.001, respectively), and the median albumin level was higher in the group without active inflammation (P<0.001).
Medication Use
The medications used at the time of MRE examination among patients with clinical remission of CD were 5-aminosalicylic acid (5-ASA) in 56 patients (91.8%), azathioprine in 34 patients (55.7%), tumor necrosis factor α (TNF-α) inhibitors in 10 patients (16.4%), corticosteroids in 1 patient (1.6%), methotrexate in 1 patient (1.6%), and none in 1 patient (1.6%). Among 61 patients in the clinical remission state, the need for adding other medications or increasing the dose of current medications was observed in 24 patients (39.3%), and of these, addition of corticosteroids was observed in 5 patients (8.2%).
The medications used at the clinically active state of CD were 5-ASA in 95 patients (84.8%), azathioprine in 64 patients (57.1%), TNF-α inhibitors in 27 patients (24.1%), corticosteroids in 7 patients (6.3%), methotrexate in 2 patients (1.8%), and none in 1 patient (0.9%). Among 112 patients with clinically active CD, the need for adding other medications or increasing the dose of current medications was observed in 77 patients (68.8%), and addition of corticosteroids was observed in 37 patients (33%).
Outcomes of Patients with Clinical Remission of CD
In multivariate analysis, active inflammation on MRE increased the risk for relapse (hazard ratio [HR], 6.985; 95% CI, 1.024−47.649), and the risk for the need for adding other medications or increasing the dose of current medications (HR, 6.440; 95% CI, 1.432−28.966) in patients with clinical remission of CD (Table 4) . The age at diagnosis of CD and 
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the median albumin level were related to the risk for the need for adding other medications or increasing the dose of current medications. In the Kaplan-Meier analysis with the log-rank test, the presence of active inflammation on MRE imaging was significantly associated with higher cumulative probabilities of relapse (P =0.025), or the need for adding other medications or increasing the dose of current medications (P=0.029), compared with the absence of active inflammation on MRE (Fig. 2) . 
HR, hazard ratio; MRE, magnetic resonance enterography. www.irjournal.org
Outcomes of Patients with Clinically Active CD
In multivariate analysis, active inflammation on MRE increased the risk for CD-related admission (HR, 2.970; 95% CI, 1.006−8.772) in patients with clinically active CD (Table 5 ). According to the Montreal classification, patients who were diagnosed as having CD at age between 17 and 40 years (A2) had a lower risk for the need for corticosteroids (HR, 0.413; 95% CI, 0.185−0.923) and for adding other medications or increasing the dose of current medications (HR, 0.373; 95% CI, 0.197−0.707). Stricturing disease (B2) (HR, 2.383; 95% CI, 1.005−5.383) or penetrating disease (B3) (HR, 2.795; 95% CI, 1.207−6.476) increased the risk for admission, compared with nonstricturing or nonpenetrating disease (B1). Penetrating disease (B3) increased the surgical risk (HR, 5.454; 95% CI, 1.094−27.178), and structuring disease (B2) showed a trend toward an increased risk of surgery (P=0.056). The cumulative probability of admission (P =0.009) was higher in patients with active inflammation on MRE imaging than in those without (Fig. 3) .
DISCUSSION
Regular evaluation of disease activity in patients with CD is important to allow providing adequate medical or surgical therapy, and monitoring drug efficacies. [21] [22] [23] Until recently, the goal of therapy for CD was only to eliminate diseaserelated symptoms, improve the quality of life of patients, and maintain general wellness by minimizing adverse effects and long-term sequelae. 24 In recent studies, the efficacy of CDAI as an indicator of disease severity has been found to be inconclusive. 25, 26 In our study, the CDAI score was not well correlated with the risk for relapse, surgery, or the need for other medications, except for the risk of admission (HR, 1.005; 95% CI, 1.000−1.009) in patients with clinically active CD. Moreover, the CDAI score was not correlated with relapse, admission, surgery, or the need for other medications in patients with clinical remission of CD.
The new goal of treatment is no longer only clinical remission indicated by a CDAI score of <150, but also the induction and maintenance of mucosal healing. 24, 27 Patients with both deep remission (defined as CDAI scores <150) and mucosal healing seem to have better outcomes than patients with only clinical remission or only mucosal healing. 28, 29 Mucosal healing detected with MRE imaging was well correlated with the disease activity of CD. 8 In our study, mucosal 30 MRE is a radiation-free imaging technique used to obtain cross-sectional images of the small bowel, and can describe the whole of the gastrointestinal tract, including mucosal, mural, and extramural tissues. 30 Cross-sectional imaging is important in assessing diseases in parts of the small bowel that are difficult to reach by using enteroscopy. 31 MRE also has a role in the detection of complications of small-bowel CD and postoperative CD recurrence. 32 CD involvement of the proximal small bowel has a higher risk of stricturing behavior and the requirement for multiple surgeries. 33 In our study, stricturing disease (B2) and penetrating disease (B3) according to the Montreal classification increased the risk for hospitalization by more than two times, compared with nonstricturing or nonpenetrating disease (B1) in patients with clinically active CD. Moreover, penetrating disease (B3) increased the risk for surgery by more than five times. The current retrospective study provides evidence of the usefulness of MRE in assessing the prognosis of CD. The presence of active inflammation on MRE increased the risk (by more than six times) for relapse and the need for adding other medications or increasing the dose of current medica- tions in patients with clinical remission of CD. Moreover, the presence of active inflammation on MRE increased the risk for CD-related admission in patients with clinically active CD.
In a recent study, the radiologic response with CTE or MRE was associated with significant reductions in the longterm risk of hospitalization, surgery, or corticosteroid use among patients with small-bowel CD, supporting our results. 12 Complete radiologic response, defined as improvement of all lesions at a second imaging study, decreased the risk for steroid use and surgery by >60% and the risk for hospitalization by 70%. 12 In our study, we focused on the effects of the first findings of MRE imaging at the time of clinical remission and during the clinically active state in patients with CD, separately. Moreover, we included patients with L2 disease (colonic lesion) according to the Montreal classification, and analyzed the risk of clinical relapse and the need for adding other medications or increasing the dose of current medications. In this study, the risk of surgery and need for corticosteroids were not correlated with the initial MRE findings; however, the risk for clinical relapse, hospitalization, and the need for adding other medications or increasing the dose of current medications were significantly related to the findings of active inflammation on the initial MRE study. This study has some limitations. As this was a retrospective study with a chart review, there was a timing difference between remission or relapse and MRE imaging in each patient. MRE imaging was done during a long-standing clinical remission state in some patients, whereas other patients underwent imaging study immediately after clinical remission. We did not analyze the MRE findings with regard to mural thickening or edema because we only focused on the prognostic significance of the mucosal healing phase against active inflammation. Furthermore, MRE activity was not classified into specific degrees using previous alleged scoring systems such as magnetic resonance index of activity (MaRIA), Crohn' s disease activity score (CDAS), or magnetic resonance enterography global score (MEGS). Prognosis could be affected by change of treatment options or physician's decisions, but these factors were not considered. In addition, pediatric patients <18 years old were excluded, and we were not able to analyze the effects of anti-Saccharomyces cerevisiae antibody and fecal calprotectin level because of a lack of data. Colonoscopic findings were not analyzed with MRE findings because there was a time difference between the days of colonoscopic examination and MRE imaging examination, and most patients had small-bowel involvement. Further studies about the correlation between endoscopic and MRE imaging findings are needed. In another study, high CRP at the time of CD diagnosis was risk factor for hospitalization; 34 however, we were not able to find a relationship between CRP level and prognosis. This report is the first study to evaluate the clinical outcomes of findings of active inflammation on MRE imaging in patients with CD.
In conclusion, the presence of active inflammation on MRE in patients with CD at the time of clinical remission was significantly associated with a high risk of relapse and the need for adding other medications or increasing the dose of current medications. Moreover, the presence of active inflammation during the clinically active state was significantly associated with an increased risk of hospitalization. MRE might be a useful technique in monitoring disease activity in patients with CD. 
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